2024 Laboratory Reimbursement Trends and What to Expect in 2025
Revenue cycle management experts weigh in on the biggest developments of 2024 and how labs can best prepare for 2025 and beyond
Revenue cycle management experts weigh in on the biggest developments of 2024 and how labs can best prepare for 2025 and beyond
Recent developments pose reimbursement and compliance challenges for billing and coding infectious disease testing—here’s how to manage them.
The new codes have garnered attention as a future mechanism for additional reimbursement and thus deserve further discussion.
Auditing in medical laboratories is critical for reviewing processes to identify erroneous outcomes, as well as areas for improvement.
To ensure proper Medicare Part B billing and coding, your billing staff must be aware of all 22 of the newly recognized PLA codes.
Proper usage of ABN-related modifiers is a significant issue that has a direct impact on your lab’s reimbursement and compliance.
Lab leaders must be able to make a sound assessment of both the costs and benefits, and the liability risks involved.
Labs have a duty to inquire into what their billing company is up to and whether it complies with all applicable regulations.
How to explain the current state of EKRA to your lab executives.
Here are the changes to Medicare specimen collection fee and travel allowances included in the 2023 PFS and what you’ll need to know to comply.
One of the biggest danger areas that labs and their billing staffs face in COVID-19 test reimbursement is improper use of HCPCS code G2023.